Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) will present at the 2026 Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 9:35 AM PT. Dr. Hugh Davis, President and COO, will deliver the corporate presentation. A live and archived webcast will be available on the company website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ACRS
In the May 8 session, ACRS gained 1.44%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Phase 1a results | Positive | -4.3% | Positive full top-line Phase 1a ATI-052 data and lead indication update. |
| Apr 27 | Clinical update notice | Neutral | -4.3% | Announcement of upcoming ATI-052 results release and ATI-2138 indication selection. |
| Apr 08 | Conference participation | Neutral | +5.3% | Participation in virtual inflammatory skin disease conference with management fireside chat. |
| Mar 27 | Phase 2a data | Positive | +0.0% | Presentation of Phase 2a ATI-2138 ePoster showing strong week-12 efficacy measures. |
| Mar 20 | Poster announcement | Neutral | -1.3% | Announcement of upcoming Phase 2a ATI-2138 ePoster at AAD Annual Meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often seen mixed or negative price reactions, including a selloff following positive Phase 1a ATI-052 data, indicating a pattern of skepticism or profit-taking around updates.
Over the past few months, Aclaris has focused on advancing its immuno-inflammatory pipeline. Positive full top-line Phase 1a data for ATI-052 and strong Phase 2a data for ATI-2138 in atopic dermatitis were key milestones, alongside multiple conference and presentation appearances. Despite these scientific updates, price reactions have been mixed, with several clinical and pipeline communications around March–April 2026 followed by flat or negative moves. Today’s conference-participation news fits within this pattern of ongoing visibility and investor outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris’ President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
